Sanuwave Health (NASDAQ:SNWV) Now Covered by Analysts at Northland Securities

Key Points

• Northland Securities initiated coverage of Sanuwave Health (NASDAQ:SNWV) with an "outperform" rating and a price target of $55.00, suggesting a potential upside of 38.36% from its recent close.
• Other investment analysts, including Roth Capital and Wall Street Zen, have upgraded their ratings on SNWV, indicating a consensus rating of "Buy" among market analysts.
• Sanuwave Health recently reported quarterly earnings that exceeded expectations, with revenue of $10.16 million, compared to estimates of $10.14 million.

Stock analysts at Northland Securities assumed coverage on shares of Sanuwave Health (NASDAQ:SNWV - Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an "outperform" rating and a $55.00 price target on the stock. Northland Securities' price objective indicates a potential upside of 48.65% from the company's current price.

SNWV has been the topic of a number of other reports. Roth Capital lifted their price objective on shares of Sanuwave Health from $54.00 to $55.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Wall Street Zen upgraded shares of Sanuwave Health from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $55.00.

Sanuwave Health Price Performance

Shares of SNWV stock traded down $0.88 during trading hours on Wednesday, hitting $37.00. 12,068 shares of the company were exchanged, compared to its average volume of 51,097. The company has a market cap of $317.09 million, a PE ratio of -4.48 and a beta of 1.39. Sanuwave Health has a one year low of $5.21 and a one year high of $46.58. The firm has a 50-day moving average price of $37.47.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.10. The company had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Solas Capital Management LLC purchased a new stake in Sanuwave Health in the 1st quarter valued at about $20,658,000. Strategic Investment Solutions Inc. IL acquired a new stake in Sanuwave Health during the first quarter worth about $47,000. AWM Investment Company Inc. acquired a new stake in Sanuwave Health in the first quarter valued at approximately $18,153,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Sanuwave Health in the second quarter worth approximately $126,000. Finally, New York State Common Retirement Fund acquired a new position in Sanuwave Health during the second quarter worth about $102,000. 42.53% of the stock is currently owned by institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.